SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Street Walker who wrote (1400)11/5/1999 7:48:00 AM
From: Dan P  Read Replies (1) | Respond to of 5582
 
Although the withdrawal of the publication is unfortunate,
the results aren't changed. The major advantage of a
publication is that the results are in black and white
and we have the benefit of a peer review publication.
Cold season is upon us, and there is great demand for the
product.

In the Chicago area, I first learned of this a few
days ago from a radio talk show, and the host indicated
he went to a lot of places before finding Zicam.

Regards

Dan



To: Street Walker who wrote (1400)11/5/1999 11:38:00 AM
From: Bo Didley  Respond to of 5582
 
>>>>>>* * * It was the fault of the Journal for not getting their job done faster and getting the results published BEFORE the second clinicals. <<<<<

Message 11817221

GUMM management had nothing to do with this. I agree it was the Journals fault and Edelman and Kovel Fuller may have taken advantage.

bo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News